Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-01-04 Long-term control of gout
| Allopurinol |
|
First Choice
|
| Tablets 100mg, 300mg |
 LSCMMG: Gout Management Summary Guidelines |
|
| Febuxostat Adenuric® |
|
Second Choice
|
| Tablets f/c 80mg, 120mg For patients who are intolerant of allopurinol or for whom allopurinol is contraindicated |
|
LSCMMG: Gout Management Summary Guidelines MHRA: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease |
|
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Gout Management Summary Guidelines
- LSCMMG: Gout Management Summary Guidelines
- LSCMMG: Gout Management Summary Guidelines
- LSCMMG: Primary Care Constipation Guidelines
- MHRA advice regarding risk of serious hypersensitivity reactions
- MHRA Drug Safety update July 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE HST25 - Lumasiran for treating primary hyperoxaluria type 1
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG100: Rheumatoid arthritis in adults: management
- NICE NG219: Gout: diagnosis and management
- NICE NG226: Osteoarthritis in over 16s: diagnosis and management
- NICE TA164: Hyperuricaemia - febuxostat
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
- NICE: Lumasiran for treating primary hyperoxaluria type 1